logo

Anavex Life Sciences Corp. (AVXL)



Trade AVXL now with
  Date
  Headline
7/29/2019 7:14:01 AM Anavex Life Sciences Receives Positive Opinion For Orphan Designation From EMA For ANAVEX®2-73 For Rett Syndrome
6/25/2019 7:20:19 AM Anavex Life Sciences Says First Patient Dosed In Extension Study To Its U.S. Phase 2 Clinical Trial Of ANAVEX2-73
6/6/2019 7:18:10 AM Anavex Life Sciences Announces First Patient Dosed In Phase 2 Clinical Trial Of ANAVEX2-73
3/18/2019 7:09:48 AM Anavex Life Sciences Announces First Patient Dosed In Phase 2 Clinical Trial Of ANAVEX®2-73 For Rett Syndrome In U.S.
2/7/2019 7:24:42 AM Anavex Life Sciences Q1 Net Loss $7.33 Mln Or $0.16/Shr Vs Loss $4.06 Mln Or $0.09/Shr Last Year
1/2/2019 7:03:19 AM Anavex Life Sciences Appoints Walter Kaufmann To Chief Medical Officer
10/26/2018 9:32:12 AM Anavex Life Sciences Presents New Three-Year, Longitudinal Efficacy Data For ANAVEX 2-73 In Alzheimer’s Disease
10/19/2018 7:05:45 AM Anavex Life Sciences Reports FDA Approval Of IND For Phase 2 Trial Of ANAVEX2-73 In Patients With Rett Syndrome
8/9/2018 7:20:57 AM Anavex Life Sciences Q3 Net Loss $2.8 Mln Or $0.06/Shr Vs Loss $3.6 Mln Or $0.04/Shr Last Year
7/25/2018 9:04:57 AM Anavex Life Sciences Presents New Data Identifying Treatment Response Biomarkers In Alzheimer’s Disease Patients
7/9/2018 7:02:25 AM Anavex Life Sciences Gets Approval To Initiate Phase 2 Clinical Trial Of ANAVEX®2-73 For Parkinson’s Disease Dementia
7/3/2018 7:01:27 AM Anavex Life Sciences Gets Approval To Initiate Phase 2b/3 Clinical Trial Of ANAVEX®2-73 For Early Alzheimer’s Disease
5/10/2018 7:16:17 AM Anavex Life Sciences Q2 Net Loss Widens To $4.8 Mln Or $0.11/shr From $1.5 Mln Or $0.04/shr Last Year
4/17/2018 7:08:11 AM Anavex Life Sciences To Initiate Phase 2 Study Of ANAVEX®2-73 In Parkinson’s Disease Dementia
3/5/2018 7:08:00 AM Anavex Life Sciences Appoints Stephan Toutain As SVP Of Operations And Claus Van Der Velden To Board